Dry Eye Disease (DED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Dry Eye Disease (DED) Market Outlook

Thelansis’s “Dry Eye Disease (DED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dry Eye Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dry Eye Disease (DED) Overview

Dry eye disease (DED), also referred to as keratoconjunctivitis sicca, is a prevalent and persistent condition affecting the ocular surface. It is characterized by an inability to produce an adequate quantity or quality of tears to moisturize the eyes. Several common risk factors contribute to this syndrome, including aging, being female, exposure to low-humidity environments, using certain systemic medications, and autoimmune disorders. DED is categorized into two main types: "dry eye with reduced tear production," referred to as aqueous deficient, and "dry eye with increased tear film evaporation," known as the hyper-evaporative type. Among those affected, about 10% suffer from aqueous deficient DED, while more than 80% experience the hyper-evaporative type, often related to meibomian gland dysfunction (MGD) or a combination of both. The consequences of DED can be substantial, significantly impacting one's vision and overall quality of life. The associated symptoms often interfere with everyday tasks such as writing, reading, or working on video display monitors. Consequently, the primary objectives of DED treatment are to alleviate ocular discomfort, enhance the patient's quality of life, and restore the ocular surface and tear film to their natural states, preventing any further harm to the eye tissue and cornea. Various pharmacological therapies are available as part of the treatment arsenal.

• The prevalence of DED in the general population stands at 5.28%. The condition is more prevalent among females, affecting 7.78%, compared to 2.96% among males. Furthermore, DED becomes more common with age, with a rate of 0.20% among those aged 2-17 years, increasing significantly to 11.66% for individuals aged 50 years or older.
• The annual prevalence rates show an upward trend, rising from 0.8% to 3.0% overall, from 1.4% to 4.5% in females, and from 0.3% to 1.6% in males.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: